Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 6/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 4/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19086028 | 0.81 | ALDH1A1 (0.47) | HDAC6PRMT5WDR77ALDH1A1KDM4E | |
| SCHEMBL1174513 | 0.79 | HDAC6 (0.72) | HDAC6PRMT5WDR77KDM4EKDM1A | |
| SCHEMBL16794217 | 0.77 | BTK (0.60) | HDAC6PRMT5WDR77NR1H2 | |
| SCHEMBL978284 | 0.75 | HDAC6 (0.59) | HDAC6PRMT5WDR77KDM4EMKNK1 | |
| SCHEMBL1174301 | 0.75 | ADORA1 (0.57) | HDAC6ALDH1A1KDM4ELMNAESR2 | |
| SCHEMBL19086033 | 0.75 | ALDH1A1 (0.51) | ALDH1A1KDM4ELMNA | |
| SCHEMBL19085980 | 0.74 | PRMT5 (0.40) | HDAC6PRMT5WDR77 | |
| SCHEMBL19086223 | 0.74 | METTL3 (0.43) | HDAC6PRMT5WDR77ALDH1A1KDM4E | |
| SCHEMBL743782 | 0.74 | HDAC6 (0.54) | HDAC6PRMT5WDR77ALDH1A1KDM4E | |
| SCHEMBL8555269 | 0.74 | HDAC6 (0.54) | HDAC6KDM4EMKNK1ESR2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017114275-A1 | COMPOUND FOR INHIBITING ROCK, PREPARATION METHOD AND USE OF SAME | 成都先导药物开发有限公司 | 2017-07-06 | — | — | WO | disclosed |
| US-20150290228-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150290228-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | BCL6, BCL3, BCL9 | HDAC6 971/4885PRMT5 2056/4885WDR77 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.